Your first appointment at our Metairie clinic includes a consultation with a medical provider, a review of your health history, and diagnostic testing if needed
Initial investigations into the cardiovascular safety effects of glucose-lowering medications in patients with T2D revealed an unexpected reduction in CV complications and mortality with the use glucagon-like peptide 1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is)
With its regenerative capabilities, anti-inflammatory properties, and gut-protective benefits, this peptide can be a vital tool in your horse's recovery and performance maintenance
prescribing information, revised in December 2025, integrates these indications for both injection and tablet formulations, while incorporating updated guidance on severe gastrointestinal events, acute kidney injury, and periprocedural aspiration risk